Clinical Trial Update: Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update on selinexor as maintenance therapy after systemic treatment in patients with p53 wild-type, advanced or recurrent endometrial can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Selinexor (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Endometrial Cancer | Phase 3 | Status: RECRUITING